when were glp 1 agonists approved GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction Timeline of critical milestones in
Description
Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease
No compounding
They are located throughout the body
Several generic GLP-1s are expected on the market in Canada later this year
Regulates appetite and blood sugar
It seems like asking someone to stay on a weekly injection indefinitely is a much harder sell
